516 related articles for article (PubMed ID: 12654251)
21. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
[TBL] [Abstract][Full Text] [Related]
22. STI-571: an anticancer protein-tyrosine kinase inhibitor.
Roskoski R
Biochem Biophys Res Commun; 2003 Oct; 309(4):709-17. PubMed ID: 13679030
[TBL] [Abstract][Full Text] [Related]
23. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
[TBL] [Abstract][Full Text] [Related]
24. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
Atwell S; Adams JM; Badger J; Buchanan MD; Feil IK; Froning KJ; Gao X; Hendle J; Keegan K; Leon BC; Müller-Dieckmann HJ; Nienaber VL; Noland BW; Post K; Rajashankar KR; Ramos A; Russell M; Burley SK; Buchanan SG
J Biol Chem; 2004 Dec; 279(53):55827-32. PubMed ID: 15507431
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.
Fabbro D; Manley PW; Jahnke W; Liebetanz J; Szyttenholm A; Fendrich G; Strauss A; Zhang J; Gray NS; Adrian F; Warmuth M; Pelle X; Grotzfeld R; Berst F; Marzinzik A; Cowan-Jacob SW; Furet P; Mestan J
Biochim Biophys Acta; 2010 Mar; 1804(3):454-62. PubMed ID: 20152788
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
Azam M; Latek RR; Daley GQ
Cell; 2003 Mar; 112(6):831-43. PubMed ID: 12654249
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
[TBL] [Abstract][Full Text] [Related]
28. c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution.
Badger J; Grover P; Shi H; Panjarian SB; Engen JR; Smithgall TE; Makowski L
Biochemistry; 2016 Jun; 55(23):3251-60. PubMed ID: 27166638
[TBL] [Abstract][Full Text] [Related]
29. Two amino acid residues confer different binding affinities of Abelson family kinase SRC homology 2 domains for phosphorylated cortactin.
Gifford SM; Liu W; Mader CC; Halo TL; Machida K; Boggon TJ; Koleske AJ
J Biol Chem; 2014 Jul; 289(28):19704-13. PubMed ID: 24891505
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
31. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Tokarski JS; Newitt JA; Chang CY; Cheng JD; Wittekind M; Kiefer SE; Kish K; Lee FY; Borzillerri R; Lombardo LJ; Xie D; Zhang Y; Klei HE
Cancer Res; 2006 Jun; 66(11):5790-7. PubMed ID: 16740718
[TBL] [Abstract][Full Text] [Related]
32. Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide.
Donaldson LW; Gish G; Pawson T; Kay LE; Forman-Kay JD
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14053-8. PubMed ID: 12384576
[TBL] [Abstract][Full Text] [Related]
33. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases.
Reeves PM; Bommarius B; Lebeis S; McNulty S; Christensen J; Swimm A; Chahroudi A; Chavan R; Feinberg MB; Veach D; Bornmann W; Sherman M; Kalman D
Nat Med; 2005 Jul; 11(7):731-9. PubMed ID: 15980865
[TBL] [Abstract][Full Text] [Related]
34. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
35. Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core.
Chen S; O'Reilly LP; Smithgall TE; Engen JR
J Mol Biol; 2008 Nov; 383(2):414-23. PubMed ID: 18775435
[TBL] [Abstract][Full Text] [Related]
36. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
Modugno M; Casale E; Soncini C; Rosettani P; Colombo R; Lupi R; Rusconi L; Fancelli D; Carpinelli P; Cameron AD; Isacchi A; Moll J
Cancer Res; 2007 Sep; 67(17):7987-90. PubMed ID: 17804707
[TBL] [Abstract][Full Text] [Related]
37. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
38. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.
Reeves PM; Smith SK; Olson VA; Thorne SH; Bornmann W; Damon IK; Kalman D
J Virol; 2011 Jan; 85(1):21-31. PubMed ID: 20962097
[TBL] [Abstract][Full Text] [Related]
39. The Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding.
Chen S; Brier S; Smithgall TE; Engen JR
Protein Sci; 2007 Apr; 16(4):572-81. PubMed ID: 17327393
[TBL] [Abstract][Full Text] [Related]
40. Conformational disturbance in Abl kinase upon mutation and deregulation.
Iacob RE; Pene-Dumitrescu T; Zhang J; Gray NS; Smithgall TE; Engen JR
Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1386-91. PubMed ID: 19164531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
